Primetime Life Sciences, LLC

[Not Yet Scheduled]
Primetime Life Sciences' mission is to expedite the discovery and development of new and smart treatments using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Primetime’s most advanced project is the development of antidepressants by a novel mechanism of action.
The lead compound PTLS-181 is a potent and selective adenosine A1R agonist and has a significant advantage over other adenosine A1R agonists. A1R activation has a rapid anti-depressive effect via rapid up-regulation of Homer 1a in the mPFC. PTLS-181 has shown efficacy in a mouse model of depression and has an excellent safety profile.
The project is supported by a non-dilutive SBIR Fast-Track grant of $2.93 million. Currently, we are performing IND enabling studies and planning to file an IND application in June 2022 to treat depression. Once we receive an IND approval, we will initiate clinical trials, and it will also increase project valuation and interest for partnering/licensing the project.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
PTLS-181
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
President & CEO
Primetime Life Sciences LLC